Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Delic Holdings Corp DELCF

Delic Holdings Corp. is a Canada-based company. The Company owns and operates a self-sustaining umbrella of businesses in the psychedelic ecosystem consisting of media, science and health. The Company’s subsidiaries include Delic Corp., Delic Labs Inc. (Delic Labs), Ketamine Infusion Centers, LLC (KIC), and Ketamine Wellness Centers, LLC (KWC). Delic Corp. is an international media ecosystem... see more

GREY:DELCF - Post Discussion

View:
Post by yopmemama021 on Jun 23, 2021 5:33pm

DELC

$DELC @$0.305, tiny mc , trading 7X average volume 

 

Matt Stang’s  interview last week with CEO of Departure Capital 

 

He discusses: 

 

  • the significance of their newly acquired KIC 
    • plan to expand the ketamine business and become the leading psychedelic clinic chain in America 
    • it means DELC can offer an entire customer journey from their multimedia informatory platform to their clinics 
    • by creating a  self sustaining ecosystem where people can become curious, learn, gain knowledge and actually actively seek treatment 

 

 

  • the opportunity the psychedelic market holds
    • major demand for novel interventions in various psychiatric crises 
      • addiction, PTSD, anxiety, depression 
    • beyond the clinical world, the wellness/ naturopathic market is massive 
    • observation into the multi trillion $ wellness market leads Matt Stang to believe the psychedelic market has potential to match that

 

 

 

  • the difference between DELC and competitors 
    • Matt Stang believes  the masses need this therapy and DELC ’s vision is making it accessible at all 
    • insurance accessible, price accessible 
    • putting centres in smaller places that don’t have as many people and resources 

 

upcoming regulatory changes 

  • MDMA and psilocybin are both in phase 3  clinical trials with the FDA
  • results from those trials expected by the end of the year 
  • considering the relative efficacy of these novel interventions (50-70%) compared to common pharmaceutical (4-5% effective in complete treatment of mental disorders) he predicts some sort of approval for both in 2022

 

full interview 

https://www.youtube.com/watch?v=gfvlzTlGEh8

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities